相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Dmp1 Physically Interacts with p53 and Positively Regulates p53's Stability, Nuclear Localization, and Function
Donna P. Frazier et al.
CANCER RESEARCH (2012)
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Dawid Walerych et al.
CARCINOGENESIS (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents
C. C. Wong et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Carboxylesterases 1 and 2 Hydrolyze Phospho-Nonsteroidal Anti-Inflammatory Drugs: Relevance to Their Pharmacological Activity
Chi C. Wong et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The novel phospho-non-steroidal anti-inflammatory drugs, OXT-328, MDC-22 and MDC-917, inhibit adjuvant-induced arthritis in rats
L. Huang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Oxidative Stress Mediates through Apoptosis the Anticancer Effect of Phospho-Nonsteroidal Anti-Inflammatory Drugs: Implications for the Role of Oxidative Stress in the Action of Anticancer Agents
Yu Sun et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Critical Roles of DMP1 in Human Epidermal Growth Factor Receptor 2/neu-Arf-p53 Signaling and Breast Cancer Development
Pankaj Taneja et al.
CANCER RESEARCH (2010)
ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non-Small Cell Lung Cancer
Anja Baumgart et al.
CANCER RESEARCH (2010)
Phospho-Sulindac (OXT-328), a Novel Sulindac Derivative, Is Safe and Effective in Colon Cancer Prevention in Mice
Gerardo G. Mackenzie et al.
GASTROENTEROLOGY (2010)
A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity
Gary A. Piazza et al.
CANCER PREVENTION RESEARCH (2009)
Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect
Wenping Zhao et al.
CARCINOGENESIS (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
Jack Cuzick et al.
LANCET ONCOLOGY (2009)
Posttranslational Modification of p53: Cooperative Integrators of Function
David W. Meek et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
F2-isoprostanes in human health and diseases:: From molecular mechanisms to clinical implications
Samar Basu
ANTIOXIDANTS & REDOX SIGNALING (2008)
The thioredoxin system: a key target in tumour and endothelial cells
A. Mukherjee et al.
BRITISH JOURNAL OF RADIOLOGY (2008)
The Thioredoxin System Mediates Redox-Induced Cell Death in Human Colon Cancer Cells: Implications for the Mechanism of Action of Anticancer Agents
Yu Sun et al.
CANCER RESEARCH (2008)
Acetylation is indispensable for p53 activation
Yi Tang et al.
CELL (2008)
The ADAM17-amphiregulin-EGFR axis in mammary development and cancer
Mark D. Sternlicht et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APCmin/+ mice proportionally to their tumor inhibitory effect:: Implications for the role of PPARδ in carcinogenesis
N Ouyang et al.
CARCINOGENESIS (2006)
Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage
JM Solomon et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer
SJ Kim et al.
CLINICAL CANCER RESEARCH (2005)
p53 mutation heterogeneity in cancer
T Soussi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status
SF Marshall et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
TO Nielsen et al.
CLINICAL CANCER RESEARCH (2004)
Kit and FCεRI mediate unique and convergent signals for release of inflammatory mediators from human mast cells
TR Hundley et al.
BLOOD (2004)
Targeting epidermal growth factor receptor - are we missing the mark?
JE Dancey et al.
LANCET (2003)
A randomized trial of aspirin to prevent colorectal adenomas
JA Baron et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation
A Ito et al.
EMBO JOURNAL (2002)
Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer
S Tsutsui et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
分享论文
